• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人诱导多能干细胞在 cGMP 条件下的培养方法。

Human-Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions.

机构信息

Allele Biotechnology and Pharmaceuticals, Inc., San Diego, California.

出版信息

Curr Protoc Stem Cell Biol. 2020 Sep;54(1):e117. doi: 10.1002/cpsc.117.

DOI:10.1002/cpsc.117
PMID:32649060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7507179/
Abstract

The discovery of induced pluripotent stem cells (iPSCs) revolutionized the approach to cell therapy in regenerative medicine. Reprogramming of somatic cells into an embryonic-like pluripotent state provides an invaluable resource of patient-specific cells of any lineage. Implementation of procedures and protocols adapted to current good manufacturing practice (cGMP) requirements is critical to ensure robust and consistent high-quality iPSC manufacturing. The technology developed at Allele Biotechnology for iPSC generation under cGMP conditions is a powerful platform for derivation of pluripotent stem cells through a footprint-free, feeder-free, and xeno-free reprogramming method. The cGMP process established by Allele Biotechnology entails fully cGMP compliant iPSC lines where the entire manufacturing process, from tissue collection, cell reprogramming, cell expansion, cell banking and quality control testing are adopted. Previously, we described in this series of publications how to create iPSCs using mRNA only, and how to do so under cGMP conditions. In this article, we describe in detail how to culture, examine and storage cGMP-iPSCs using reagents, materials and equipment compliant with cGMP standards. © 2020 The Authors. Basic Protocol 1: iPSC Dissociation Support Protocol 1: Stem cell media Support Protocol 2: ROCK inhibitor preparation Support Protocol 3: Vitronectin coating Basic Protocol 2: iPSC Cryopreservation Basic Protocol 3: iPSC Thawing.

摘要

诱导多能干细胞(iPSCs)的发现彻底改变了再生医学中细胞治疗的方法。体细胞重编程为胚胎样多能状态为任何谱系的患者特异性细胞提供了宝贵的资源。实施适应现行良好生产规范(cGMP)要求的程序和方案对于确保稳健且一致的高质量 iPSC 制造至关重要。Allele Biotechnology 开发的在 cGMP 条件下生成 iPSC 的技术是通过无足迹、无饲养层和无异种的重编程方法衍生多能干细胞的强大平台。Allele Biotechnology 建立的 cGMP 工艺包括完全符合 cGMP 标准的 iPSC 系,其中采用了从组织采集、细胞重编程、细胞扩增、细胞储存和质量控制测试的整个制造过程。在此之前,我们在本系列出版物中描述了如何仅使用 mRNA 创建 iPSC,以及如何在 cGMP 条件下进行。在本文中,我们详细描述了如何使用符合 cGMP 标准的试剂、材料和设备来培养、检查和储存 cGMP-iPSC。 © 2020 作者。 基本方案 1:iPSC 解离 支持方案 1:干细胞培养基 支持方案 2:ROCK 抑制剂制备 支持方案 3:纤连蛋白包被 基本方案 2:iPSC 冷冻保存 基本方案 3:iPSC 解冻。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/824e39a71ba2/CPSC-54-e117-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/7135e6b536e3/CPSC-54-e117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/67f4fd39c032/CPSC-54-e117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/a41014df2a1d/CPSC-54-e117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/def8ce0388ef/CPSC-54-e117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/824e39a71ba2/CPSC-54-e117-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/7135e6b536e3/CPSC-54-e117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/67f4fd39c032/CPSC-54-e117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/a41014df2a1d/CPSC-54-e117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/def8ce0388ef/CPSC-54-e117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934b/7507179/824e39a71ba2/CPSC-54-e117-g005.jpg

相似文献

1
Human-Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions.人诱导多能干细胞在 cGMP 条件下的培养方法。
Curr Protoc Stem Cell Biol. 2020 Sep;54(1):e117. doi: 10.1002/cpsc.117.
2
cGMP Generation of Human Induced Pluripotent Stem Cells with Messenger RNA.利用信使核糖核酸产生人诱导多能干细胞的环磷酸鸟苷
Curr Protoc Stem Cell Biol. 2016 Nov;39(1):4A.6.1-4A.6.25. doi: 10.1002/cpsc.18.
3
cGMP-Compliant Expansion of Human iPSC Cultures as Adherent Monolayers.符合cGMP标准的人诱导多能干细胞贴壁单层培养扩增
Methods Mol Biol. 2016;1357:221-9. doi: 10.1007/7651_2015_243.
4
cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.cGMP 制造的人诱导多能干细胞可用于临床前和临床应用。
Stem Cell Reports. 2015 Oct 13;5(4):647-59. doi: 10.1016/j.stemcr.2015.08.015. Epub 2015 Sep 24.
5
Derivation, Expansion, and Motor Neuron Differentiation of Human-Induced Pluripotent Stem Cells with Non-Integrating Episomal Vectors and a Defined Xenogeneic-free Culture System.人诱导多能干细胞的无整合性附加体载体的诱导、扩增和运动神经元分化,以及定义的无异种细胞培养系统。
Mol Neurobiol. 2016 Apr;53(3):1589-1600. doi: 10.1007/s12035-014-9084-z. Epub 2015 Feb 10.
6
Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.符合 cGMP 标准的人诱导多能干细胞的长期稳定性和分化潜能
Int J Mol Sci. 2019 Dec 23;21(1):108. doi: 10.3390/ijms21010108.
7
Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions.人成纤维细胞在无动物血清条件下向诱导多能干细胞的重编程。
Stem Cells. 2010 Jan;28(1):36-44. doi: 10.1002/stem.248.
8
A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells.一种定义明确的无动物来源和非饲养层的培养体系,用于衍生、扩增和直接分化无转基因的患者特异性诱导多能干细胞。
Biomaterials. 2014 Mar;35(9):2816-26. doi: 10.1016/j.biomaterials.2013.12.050. Epub 2014 Jan 9.
9
Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood.从少量冷冻保存的血液中快速高效地生成无转基因 iPSC。
Stem Cell Rev Rep. 2015 Aug;11(4):652-65. doi: 10.1007/s12015-015-9586-8.
10
Scalable production of transplantable dopaminergic neurons from hESCs and iPSCs in xeno-free defined conditions.在无血清无动物成分的限定条件下,从人胚胎干细胞和诱导多能干细胞中可扩展生产可移植的多巴胺能神经元。
Curr Protoc Stem Cell Biol. 2012 Aug;Chapter 2:Unit2D.12. doi: 10.1002/9780470151808.sc02d12s22.

引用本文的文献

1
Hematopoietic stem cells and HSCs-derived from pluripotent stem cells: a hopeful outlook in cell-based therapeutics.造血干细胞以及源自多能干细胞的造血干细胞:基于细胞的治疗的一个充满希望的前景。
Mol Biol Rep. 2025 Jun 30;52(1):657. doi: 10.1007/s11033-025-10730-w.
2
Human induced pluripotent stem cell-derived cardiomyocytes and their use in a cardiac organ-on-a-chip to assay electrophysiology, calcium and contractility.人诱导多能干细胞衍生的心肌细胞及其在心脏芯片中用于检测电生理学、钙和收缩性的应用。
Nat Protoc. 2025 Apr 7. doi: 10.1038/s41596-025-01166-4.
3
Time-efficient strategies in human iPS cell-derived pancreatic progenitor differentiation and cryopreservation: advancing towards practical applications.

本文引用的文献

1
cGMP Generation of Human Induced Pluripotent Stem Cells with Messenger RNA.利用信使核糖核酸产生人诱导多能干细胞的环磷酸鸟苷
Curr Protoc Stem Cell Biol. 2016 Nov;39(1):4A.6.1-4A.6.25. doi: 10.1002/cpsc.18.
2
Preparing for first human trial of induced pluripotent stem cell-derived cells for Parkinson's disease: an interview with Jun Takahashi.诱导多能干细胞衍生细胞用于帕金森病的首次人体试验准备工作:对高桥纯的采访
Regen Med. 2019 Feb;14(2):93-95. doi: 10.2217/rme-2018-0158. Epub 2019 Jan 15.
3
Human Pluripotent Stem Cell Culture: Current Status, Challenges, and Advancement.
人诱导多能干细胞来源的胰腺祖细胞分化与冷冻保存中的高效策略:迈向实际应用
Stem Cell Res Ther. 2024 Dec 18;15(1):483. doi: 10.1186/s13287-024-04068-6.
4
Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny.线粒体突变异质性增加会在多能干细胞及其分化后代中诱导衰老表型。
Aging Cell. 2025 Mar;24(3):e14402. doi: 10.1111/acel.14402. Epub 2024 Dec 16.
5
Origin of Chromosome 12 Trisomy Surge in Human Induced Pluripotent Stem Cells (iPSCs).人类诱导多能干细胞(iPSCs)中12号染色体三体激增的起源。
bioRxiv. 2025 Jan 23:2024.12.02.626470. doi: 10.1101/2024.12.02.626470.
6
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.将诱导多能干细胞(iPSC)技术与基于嵌合抗原受体(CAR)的免疫疗法相结合:最新进展、挑战与未来前景。
Front Cell Dev Biol. 2024 Nov 18;12:1491282. doi: 10.3389/fcell.2024.1491282. eCollection 2024.
7
A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows.一种新型重组纤连蛋白变体支持无动物定义工作流程中多能干细胞的扩增和分化。
Cells. 2024 Sep 17;13(18):1566. doi: 10.3390/cells13181566.
8
Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group.用于临床应用的 iPS 细胞生成的生物工艺学考虑因素:来自 ISCT 新兴再生医学技术工作组的观点。
Cytotherapy. 2024 Nov;26(11):1275-1284. doi: 10.1016/j.jcyt.2024.05.024. Epub 2024 May 31.
9
On-Chip Neural Induction Boosts Neural Stem Cell Commitment: Toward a Pipeline for iPSC-Based Therapies.片上神经诱导增强神经干细胞的定向分化:迈向基于 iPSC 的治疗方法的流水线。
Adv Sci (Weinh). 2024 Jul;11(25):e2401859. doi: 10.1002/advs.202401859. Epub 2024 Apr 24.
10
Beyond waste: understanding urine's potential in precision medicine.超越浪费:理解尿液在精准医学中的潜力。
Trends Biotechnol. 2024 Aug;42(8):953-969. doi: 10.1016/j.tibtech.2024.01.009. Epub 2024 Feb 17.
人类多能干细胞培养:现状、挑战与进展
Stem Cells Int. 2018 Nov 22;2018:7396905. doi: 10.1155/2018/7396905. eCollection 2018.
4
'Reprogrammed' stem cells approved to mend human hearts for the first time.“重编程”干细胞首次获批用于修复人类心脏。
Nature. 2018 May;557(7707):619-620. doi: 10.1038/d41586-018-05278-8.
5
Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process.诱导多能干细胞:在重编程过程中追求遗传稳定性的进展。
Int J Mol Sci. 2017 Sep 13;18(9):1952. doi: 10.3390/ijms18091952.
6
Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration.用于黄斑变性的自体诱导干细胞衍生视网膜细胞
N Engl J Med. 2017 Aug 24;377(8):792-793. doi: 10.1056/NEJMc1706274.
7
Addressing the ethical issues raised by synthetic human entities with embryo-like features.解决由具有胚胎样特征的合成人类实体引发的伦理问题。
Elife. 2017 Mar 21;6:e20674. doi: 10.7554/eLife.20674.
8
Induced pluripotent stem cell technology: a decade of progress.诱导多能干细胞技术:十年进展
Nat Rev Drug Discov. 2017 Feb;16(2):115-130. doi: 10.1038/nrd.2016.245. Epub 2016 Dec 16.
9
Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions.与特定培养条件相关的人类胚胎干细胞中遗传和表观遗传不稳定性风险增加。
PLoS One. 2015 Feb 25;10(2):e0118307. doi: 10.1371/journal.pone.0118307. eCollection 2015.
10
A comparison of non-integrating reprogramming methods.非整合重编程方法的比较。
Nat Biotechnol. 2015 Jan;33(1):58-63. doi: 10.1038/nbt.3070. Epub 2014 Dec 1.